These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 19953500)
21. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. van Puijenbroek EP; Bate A; Leufkens HG; Lindquist M; Orre R; Egberts AC Pharmacoepidemiol Drug Saf; 2002; 11(1):3-10. PubMed ID: 11998548 [TBL] [Abstract][Full Text] [Related]
22. Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Wechwithan S; Suwankesawong W; Sornsrivichai V; McNeil EB; Jiraphongsa C; Chongsuvivatwong V Regul Toxicol Pharmacol; 2014 Oct; 70(1):407-12. PubMed ID: 24945744 [TBL] [Abstract][Full Text] [Related]
23. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. de Langen JJ; van Puijenbroek EP Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271 [TBL] [Abstract][Full Text] [Related]
24. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Golomb BA; McGraw JJ; Evans MA; Dimsdale JE Drug Saf; 2007; 30(8):669-75. PubMed ID: 17696579 [TBL] [Abstract][Full Text] [Related]
25. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Hou Y; Ye X; Wu G; Cheng G; Du X; He J Expert Opin Drug Saf; 2014 Jul; 13(7):853-7. PubMed ID: 24918197 [TBL] [Abstract][Full Text] [Related]
26. Muscle rupture associated with statin use. Ekhart C; de Jong L; Gross-Martirosyan L; van Hunsel F Br J Clin Pharmacol; 2016 Aug; 82(2):473-7. PubMed ID: 27074553 [TBL] [Abstract][Full Text] [Related]
27. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724 [TBL] [Abstract][Full Text] [Related]
28. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Motola D; Vargiu A; Leone R; Conforti A; Moretti U; Vaccheri A; Velo G; Montanaro N Drug Saf; 2008; 31(7):609-16. PubMed ID: 18558794 [TBL] [Abstract][Full Text] [Related]
29. Drug-related nephrotoxic and ototoxic reactions : a link through a predictive mechanistic commonality. Verdel BM; van Puijenbroek EP; Souverein PC; Leufkens HG; Egberts AC Drug Saf; 2008; 31(10):877-84. PubMed ID: 18759511 [TBL] [Abstract][Full Text] [Related]
30. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Fraunfelder FW; Richards AB Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555 [TBL] [Abstract][Full Text] [Related]
31. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Conforti A; Chiamulera C; Moretti U; Colcera S; Fumagalli G; Leone R Curr Drug Saf; 2007 Jan; 2(1):47-63. PubMed ID: 18690950 [TBL] [Abstract][Full Text] [Related]
32. Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena. Hippius M; Farker K; Helble S; Hoffmann A Int J Clin Pharmacol Ther; 2002 Mar; 40(3):97-101. PubMed ID: 11911604 [TBL] [Abstract][Full Text] [Related]
33. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? Sessa M; Rafaniello C; Scavone C; Mascolo A; di Mauro G; Fucile A; Rossi F; Sportiello L; Capuano A Expert Opin Drug Saf; 2018 May; 17(5):457-465. PubMed ID: 29619841 [TBL] [Abstract][Full Text] [Related]
34. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Moulis G; Béné J; Sommet A; Sailler L; Lapeyre-Mestre M; Montastruc JL; Lupus; 2012 Jul; 21(8):885-9. PubMed ID: 22333565 [TBL] [Abstract][Full Text] [Related]
35. Post-Marketing Surveillance of Statins-A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance. Pop G; Farcaș A; Butucă A; Morgovan C; Arseniu AM; Pumnea M; Teodoru M; Gligor FG Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558987 [TBL] [Abstract][Full Text] [Related]
36. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. Juhlin K; Ye X; Star K; Norén GN Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706 [TBL] [Abstract][Full Text] [Related]
37. Amyotrophic lateral sclerosis associated with statins. A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Macías Saint-Gerons D; Castro JL Eur J Clin Pharmacol; 2019 Apr; 75(4):587-589. PubMed ID: 30470902 [No Abstract] [Full Text] [Related]
38. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related]
39. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. van Hunsel F; Talsma A; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):286-91. PubMed ID: 21351310 [TBL] [Abstract][Full Text] [Related]
40. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Roberto G; Piccinni C; D'Alessandro R; Poluzzi E Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]